X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/23/2934994/0/en/Eyenovia-Announces-Closing-of-Public-Offering.html
https://www.globenewswire.com/news-release/2024/08/12/2928746/0/en/Eyenovia-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.prnewswire.com/news-releases/formosa-pharma-and-eyenovia-announce-initiation-of-co-development-of-clobetasol-propionate-ophthalmic-suspension-0-05-for-the-treatment-of-acute-dry-eye-disease-in-united-states-302215453.html
https://www.globenewswire.com/news-release/2024/07/30/2920923/0/en/Eyenovia-SGN-Nanopharma-Announce-Collaboration-Agreement-to-Develop-Novel-Treatment-for-Chronic-Dry-Eye-Disease.html
https://www.globenewswire.com/news-release/2024/07/23/2917079/0/en/Eyenovia-and-Senju-Pharmaceutical-Co-Ltd-Sign-Collaboration-Agreement-for-Potential-New-Treatment-for-Chronic-Dry-Eye-Disease.html
https://www.globenewswire.com/news-release/2024/06/28/2905797/0/en/Eyenovia-Announces-Pricing-of-5M-Registered-Direct-Offering.html
https://www.globenewswire.com/news-release/2024/05/15/2882856/0/en/Eyenovia-Reports-First-Quarter-2024-Financial-Results-and-Provides-Updates-on-its-Myopia-Phase-III-Program-and-its-Two-FDA-Approved-Commercial-Products-Mydcombi-and-Clobetasol.html
https://www.globenewswire.com/news-release/2024/05/14/2881215/0/en/Eyenovia-to-Report-First-Quarter-2024-Results-on-Wednesday-May-15th.html
https://www.globenewswire.com/news-release/2024/04/25/2869465/0/en/Eyenovia-Provides-Clinical-and-Scientific-Update-on-FDA-Approved-Products-Mydcombi-and-Clobetasol-Propionate-Ophthalmic-Suspension.html
https://www.globenewswire.com/news-release/2024/04/08/2859046/0/en/Eyenovia-Announces-Updated-Strategy-and-Corporate-Priorities-to-Focus-on-Shareholder-Value-Generation-and-Immediate-Commercial-Opportunities.html
Market Place
Share 
